MedTrace Logo

Enhanced COPD Management in Suspected Lung Cancer Patients

NCT07543601 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2026-04-22

No results posted yet for this study

Summary

Identifying and treating COPD in patients undergoing lung cancer evaluation is crucial. Early intervention could lead to better management of both diseases, improving health status, reducing healthcare costs, and potentially increasing survival rates.

This study aims to assess the impact of early diagnosis and optimal treatment of COPD on clinical outcomes in patients under evaluation for lung cancer. The study will combine information through an open-label RCT at the Lung Cancer Investigation Unit at Lillebaelt Hospital Vejle.

The findings could inform clinical practice by emphasizing the importance of integrated care approaches for patients with coexisting COPD and lung cancer, ultimately leading to better health outcomes.

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)
  • Lung Cancer (Diagnosis)
  • Lung Neoplasm Malignant
  • Lung Carcinoma
  • Pulmonary Neoplasms
  • Pulmonary Neoplasm
  • Pulmonary Cancers
  • Pulmonary Cancer
  • Pulmonary Carcinoma
  • COPD
  • COPD - Chronic Obstructive Pulmonary Disease
  • Airflow Obstruction, Chronic

Interventions

OTHER

Tailored COPD consultations

These consultations will include assessment and treatment according to GOLD guidelines, including: Pharmacological management Smoking cessation support Referral to pulmonary rehabilitation as appropriate Referral for nutritional assessment and optimization when appropriate Referral to cardiovascular evaluation when appropriate Referral to sleep apnea evaluation when appropriate

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Sygehus Lillebaelt

    collaborator OTHER

  • Ditte Krag-Hansen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-06
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07543601 on ClinicalTrials.gov